2. I understand that this study will not be initiated without approval of the appropriate Institutional Review Committee/Independent Ethics Committee (IRB/IEC), and that all administrative requirements of the governing body of the Institution will be complied with fully. 3. Informed written consent will be obtained from all participating patients in accordance with institutional guidelines, FDA requirements as specified in Title 21 CFR, Part 50, the European Union Directive 2001/20/EC and its associated Detailed Guidances, European Union GCP Directive 2005/28/EC, the ICH Guideline for Good Clinical Practice, Section 4.8, and the terms of the Declaration of Helsinki ( 2013). 4. I will enroll patients who meet the protocol criteria for entry. 5. I understand that my signature on each completed Case Report Form (CRF) indicates that I have carefully reviewed the complete set of CRFs and accept full responsibility for the contents thereof. 6. I understand that the information presented in this study protocol is confidential, and I hereby assure that no information based on the conduct of the study will be released without prior consent from the Sponsor unless this requirement is superseded by the Food and Drug Administration, a Competent Authority of the European Union or another Regulatory Authority. Protocol Version 2.0: 11 February 2020 Investigator: Name: Telephone: Address: Signature: Date: Heat Biologics: Name: Lori McDermott, VP, Clinical Development & Regulatory Affairs Signature: Date: 11 Feb 2020 HS130- 001 3 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page TABLE OF CONTENTS Page No. INVESTIGATOR’S STATEMENT ..............................................................................................................